Spring­Works teams with Dana-Far­ber to test BC­MA com­bo; VBL restarts PhI­II tri­al af­ter FDA clears gene ther­a­py batch­es

Spring­Works Ther­a­peu­tics has a new re­search part­ner.

The Con­necti­cut bio­phar­ma an­nounced to­day that it has start­ed a re­search col­lab­o­ra­tion with the Dana-Far­ber Can­cer In­sti­tute in Boston, MA. The col­lab­o­ra­tion is de­signed to fur­ther in­ves­ti­gate nirogace­s­tat, Spring­Works’ in­ves­ti­ga­tion­al gam­ma sec­re­tase in­hibitor in con­junc­tion with a va­ri­ety of an­ti-BC­MA agents. Con­stan­tine Mit­si­ades with the Har­vard Med­ical School will serve as the prin­ci­pal in­ves­ti­ga­tor for the re­search.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.